Compare Abeona Therapeutics Inc (ABEO) vs SP Funds S&P 500 Sharia Industry Exclusions ETF (SPUS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs SP Funds S&P 500 Sharia Industry Exclusions ETF — how do they compare? Abeona Therapeutics Inc trades at $6.79 (market cap $373.32M), while SP Funds S&P 500 Sharia Industry Exclusions ETF trades at $56.93. Which is the better fit depends on your goals.
| ABEO | SPUS | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | Broad Market / Factor |
52-Week High | $7.23 | $59.51 |
52-Week Low | $4.17 | $44.65 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
SPUS trades at $57.19, up 0.94% with a bullish technical signal from moving averages. The ETF offers consistent dividends, with recent payouts of $0.03 per share. Technical indicators show support at $57 and resistance at $58, while RSI levels remain neutral. Institutional interest is growing, as seen in Farther Finance Advisors' increased holdings.
Outlook remains positive due to strong dividend strategy and institutional backing. Risks include market volatility and concentration in Sharia-compliant equities. The ETF's performance hinges on broader US equity trends and dividend sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About SP Funds S&P 500 Sharia Industry Exclusions ETF
SPUS tracks a market-cap weighted index of S&P 500 stocks that adhere to Sharia law. It screens out companies involved in non-compliant business activities such as alcohol, tobacco, gambling, and conventional finance, as well as excluding sectors like Aerospace & Defense, and Data Processing. By focusing on low-leverage stocks, SPUS provides investors with a value-conscious, ethically-aligned exposure to a diversified portfolio of large-cap U.S. equities.
Read more on SPUS →
